162 related articles for article (PubMed ID: 15715810)
1. Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder.
Hazell P
Australas Psychiatry; 2004 Dec; 12(4):369-75. PubMed ID: 15715810
[TBL] [Abstract][Full Text] [Related]
2. Update on drugs for hyperactivity in childhood.
Drug Ther Bull; 2007 May; 45(5):37-40. PubMed ID: 17536494
[TBL] [Abstract][Full Text] [Related]
3. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
[TBL] [Abstract][Full Text] [Related]
4. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.
Starr HL; Kemner J
J Natl Med Assoc; 2005 Oct; 97(10 Suppl):11S-16S. PubMed ID: 16350601
[TBL] [Abstract][Full Text] [Related]
5. [Drugs for attention deficit hyperactivity disorder].
Montañés-Rada F; Gangoso-Fermoso AB; Martíínez-Granero MA
Rev Neurol; 2009 May 1-15; 48(9):469-81. PubMed ID: 19396764
[TBL] [Abstract][Full Text] [Related]
6. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
Hong J; Dilla T; Arellano J
BMC Psychiatry; 2009 Apr; 9():15. PubMed ID: 19366449
[TBL] [Abstract][Full Text] [Related]
7. Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls.
Daughton JM; Kratochvil CJ
J Am Acad Child Adolesc Psychiatry; 2009 Mar; 48(3):240-248. PubMed ID: 19242289
[No Abstract] [Full Text] [Related]
8. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
9. Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands.
van den Ban E; Souverein PC; Swaab H; van Engeland H; Egberts TC; Heerdink ER
Atten Defic Hyperact Disord; 2010 Dec; 2(4):213-20. PubMed ID: 21258431
[TBL] [Abstract][Full Text] [Related]
10. OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder.
McBurnett K; Starr HL
Expert Opin Pharmacother; 2011 Feb; 12(2):315-24. PubMed ID: 21226641
[TBL] [Abstract][Full Text] [Related]
11. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
12. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
13. InforMatrix for attention deficit hyperactivity disorder.
Janknegt R; Faber A; Rodrigues Pereira R; Kalverdijk LJ
Expert Opin Pharmacother; 2009 Apr; 10(5):755-72. PubMed ID: 19351226
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
Gibson AP; Bettinger TL; Patel NC; Crismon ML
Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
[TBL] [Abstract][Full Text] [Related]
15. Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?
Schawo S; van der Kolk A; Bouwmans C; Annemans L; Postma M; Buitelaar J; van Agthoven M; Hakkaart-van Roijen L
Pharmacoeconomics; 2015 May; 33(5):489-509. PubMed ID: 25715975
[TBL] [Abstract][Full Text] [Related]
16. Attention deficit hyperactivity disorder in adults.
Rösler M; Casas M; Konofal E; Buitelaar J
World J Biol Psychiatry; 2010 Aug; 11(5):684-98. PubMed ID: 20521876
[TBL] [Abstract][Full Text] [Related]
17. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.
Swanson J; Gupta S; Lam A; Shoulson I; Lerner M; Modi N; Lindemulder E; Wigal S
Arch Gen Psychiatry; 2003 Feb; 60(2):204-11. PubMed ID: 12578439
[TBL] [Abstract][Full Text] [Related]
18. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments.
Prince JB
Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):13-50. PubMed ID: 16321724
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin ® LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting.
Schulz E; Fleischhaker C; Hennighausen K; Heiser P; Oehler KU; Linder M; Haessler F; Huss M; Warnke A; Schmidt M; Schulte-Markworth M; Sieder C; Klatt J; Tracik F
J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):377-85. PubMed ID: 20973708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
